SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Intel shares fall back to April levels after losing over half their value in five weeks

Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast

Ground Up Ventures appoints Navot Volk as General Partner

After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems

Buzz

Most popular

Daily

Weekly

1

From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits

2

ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years

3

Israeli digital health company TailorMed acquired in $250 million deal

4

Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company

5

Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast

Life Sciences

5 stories about Life Sciences

העימותים ו מהומות ב הפגנות ב רצועת עזה גדר

CTech’s Monday Roundup of Israeli Tech News

Former Google CEO Eric Schmidt to visit Israel. U.S. Treasury Secretary Mnuchin discusses tax reform with Israeli counterpart. Report says Israel’s life sciences industry is dominated by small scale startups

בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Israel’s Life Sciences Industry Is Dominated by Small Scale Startups

14.05.18|Lilach Baumer

65% of all Israel-based life sciences companies employ 10 people or less, according to a new report

הדמייה מ פרוייקט שער ה עיר ירושלים

Jerusalem Officials Are Setting Up a Venture Capital Fund Focused on Biotech

30.04.18|Asaf Shalev

The city is home to 150 biotech startups, a new report finds

Venture Capital Firm aMoon Aims to Raise $500 Million or More For a Second Fund

17.04.18|Lilach Baumer

Established in 2016, aMoon invests in life sciences and healthcare companies, with a focus on Israeli tech

Pontifax Raises a $240 Million Fifth Fund

01.01.18|Meir Orbach

Life sciences-focused venture capital firm Pontifax is expected to invest most of the new fund in the pharmaceutical industry

Previous Articles